These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6152277)

  • 1. Beta-adrenergic blockade alone does not decrease renal perfusion in black hypertensives.
    Brater DC; Anderson S; Kaplan NM; Ram CV
    J Hypertens; 1984 Feb; 2(1):43-8. PubMed ID: 6152277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.
    O'Callaghan WG; Laher MS; McGarry K; O'Brien E; O'Malley K
    Br J Clin Pharmacol; 1983 Oct; 16(4):417-21. PubMed ID: 6138058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension.
    Dreslinski GR; Messerli FH; Dunn FG; Suarez DH; Reisin E; Frohlich ED
    Circulation; 1982 Jun; 65(7):1365-8. PubMed ID: 6122514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nadolol beta-blockade on blood pressure in hypertension.
    Duchin KL; Vukovich RA; Dennick LG; Groel JT; Willard DA
    Clin Pharmacol Ther; 1980 Jan; 27(1):57-63. PubMed ID: 6101312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between short-term renal haemodynamic effects of propranolol and nadolol in essential hypertension: a cross-over study.
    Danesh BJ; Brunton J; Sumner DJ
    Clin Sci (Lond); 1984 Aug; 67(2):243-8. PubMed ID: 6146425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol.
    O'Connor DT; Barg AP; Duchin KL
    J Clin Pharmacol; 1982 Apr; 22(4):187-95. PubMed ID: 6124557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitation of myocardial infarct size by atenolol, nadolol and propranolol in dogs.
    Burmeister WE; Reynolds RD; Lee RJ
    Eur J Pharmacol; 1981 Oct; 75(1):7-10. PubMed ID: 6119212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
    Leenen FH; Davies RA; Fourney A
    Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockers and renal function.
    Wilkinson R
    Drugs; 1982 Mar; 23(3):195-206. PubMed ID: 6122552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol.
    Hiatt WR; Wolfel EE; Stoll S; Nies AS; Zerbe GO; Brammell HL; Horwitz LD
    Clin Pharmacol Ther; 1985 Jan; 37(1):2-6. PubMed ID: 2856902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension.
    Frohlich ED; Messerli FH; Deslinski GR; Kobrin I
    Am Heart J; 1984 Oct; 108(4 Pt 2):1141-3. PubMed ID: 6148875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta blockers and renal function: a reappraisal.
    Epstein M; Oster JR
    J Clin Hypertens; 1985 Mar; 1(1):85-99. PubMed ID: 2873206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
    Pupita F; Ansuini R; Belogi M; Pupita G; Gaggi S
    Int J Clin Pharmacol Res; 1985; 5(6):439-45. PubMed ID: 2869001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diuretics, beta-blockers or both as treatment for essential hypertension.
    Stumpe KO; Overlack O
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):189S-197S. PubMed ID: 37874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between beta-blockade, hyporeninaemic and hypotensive effect of two beta-blocking agents.
    Amery A; De Plaen JF; Fagard R; Linjen P; Reybrouck T
    Postgrad Med J; 1976; 52 Suppl 4():102-8. PubMed ID: 9626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The kidney and strategies for the treatment of hypertension.
    Hollenberg NK
    Am J Med; 1984 Oct; 77(4A):60-3. PubMed ID: 6207726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.
    Heel RC; Brogden RN; Pakes GE; Speight TM; Avery GS
    Drugs; 1980 Jul; 20(1):1-23. PubMed ID: 6105067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral hemodynamic effects of short-term nadolol administration in essential hypertension.
    Levenson J; Simon AC; Moyse D; Bouthier J; Safar ME
    Am Heart J; 1984 Oct; 108(4 Pt 2):1177-82. PubMed ID: 6148882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.